Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.

Scientific reports - 20 Aug 2015

Fu Yong, Cruz-Monserrate Zobeida, Helen Lin H, Chung Yiyin, Ji Baoan, Lin Szu-Min, Vonderfecht Steven, Logsdon Craig D, Li Chien-Feng, Ann David K

Abstract excerpt

Salivary duct carcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate. Herein, we reported the detection of somatic KRAS A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid SDC variants. Transgenic mice carrying the human oncogenic KRAS(G12V), which spatiotemporal activation by tamoxifen (TAM)-inducible Cre recombinase Ela-CreERT in the submandibular gland (SMG) ductal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Proto-Oncogene Proteins p21(ras)

Share to Salivary Gland Neoplasms

Share to Sarcoma

Source

Open in PubMed Open full text

Identifiers

PMID: 26289340
DOI: 10.1038/srep13347
PMCID: PMC4642517

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.PMID 26289340Read ↗

KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas.Semantic proximity Read ↗

Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Semantic proximity Read ↗

KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogrammingSemantic proximity Read ↗

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.Semantic proximity Read ↗

S100 genes drive metastasis in salivary gland carcinomaSemantic proximity Read ↗

Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression.Semantic proximity Read ↗

Submucosal gland duct adenoma of the esophagus: expanding the morphologic spectrum of a rare tumor entity.Semantic proximity Read ↗

Clinicopathological Characteristics and Outcomes of 23 Patients with Secretory Carcinoma of Major Salivary GlandsSemantic proximity Read ↗

Genetic mutations in salivary duct carcinoma.Semantic proximity Read ↗

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Semantic proximity Read ↗

Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Semantic proximity Read ↗

Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.